Implied Podcast
Claim This Podcastby Implied Podcast™
Podcast Overview
<p><strong>Implied</strong> tracks the companies making the biggest moves — because when a stock swings hard, something big might be changing. Each 3-minute episode breaks down what just happened and why it matters, digging into earnings, filings, and market reactions to uncover what could come next.</p>
Language
🇺🇲
Publishing Since
9/5/2025
Reach the team behind Implied Podcast
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
July 14, 2026
AppLovin Plummets 12.65% — The AI Growth Miracle or a Brutal Reality Check?
<p>AppLovin just suffered a massive 12.65% single-day crash, a shocking gut-punch for one of Wall Street's ultimate market darlings. After delivering a spectacular 14-fold return over the past three years, the stock plummeted as investors panicked over cooling growth signals and soft June data for its highly anticipated e-commerce ad rollout. Yet, with a jaw-dropping 84.5% adjusted EBITDA margin and Bank of America calling the selloff overdone, the underlying cash engine remains incredibly powerful. In this episode of Implied, we break down the mechanics behind the drop, analyze the execution risks facing their AXON AI engine, and debate whether this double-digit dip is a stellar buying opportunity or the first real crack in AppLovin’s expansion story.</p>
July 13, 2026
Moderna Plunges 10.83% — Wall Street’s Top Short Idea or a High-Stakes FDA Trap?
<p>Moderna investors just suffered massive whiplash. After hitting a fresh 52-week high, the stock plummeted 10.83% in a single day after JPMorgan caught the market off guard by naming it a top Q3 short idea. Despite securing a major new European vaccine contract, Wall Street is sounding the alarm over the company’s massive $3 billion R&D cash burn and a distinct lack of revenue guarantees. In this episode of Implied, we break down the reality behind the sudden crash and explore whether an upcoming August FDA decision will validate the bears—or trigger a massive short squeeze for the 130% YTD high-flyer. Tune in to find out how to play the market's most explosive biotech battle.</p>
July 10, 2026
Ionis Plummets 19% After Blockbuster Heart Trial Fails — Biotech Disaster or Buying Opportunity?
<p>Ionis Pharmaceuticals just suffered a brutal gut-punch, with its stock plummeting nearly <strong>19%</strong> after a highly anticipated Phase 3 heart drug trial completely missed its primary goals. The sudden failure wiped out all the momentum from a major FDA approval just weeks prior. But the real twist? Corporate insiders quietly dumped over <strong>$25 million</strong> in shares leading up to the announcement, leaving retail investors holding the bag.</p><p>In this episode of Implied, we break down the clinical disaster, unpack the suspicious insider selling, and analyze the company's explosive <strong>87% revenue growth</strong> that's still humming behind the scenes. Is this crash a warning to stay far away, or is the market overreacting to a single setback, leaving a heavily diversified biotech giant deeply undervalued? Tune in to find out if this is a dangerous trap or a rare, high-upside entry point.</p>
160 total episodes available
Deep-dive analytics for Implied Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Implied Podcast?
<p><strong>Implied</strong> tracks the companies making the biggest moves — because when a stock swings hard, something big might be changing. Each 3-minute episode breaks down what just happened and why it matters, digging into earnings, filings, and market reactions to uncover what could come next.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.